Search Within

Joachim Yahalom

  1. "Jessica Flynn"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (4)
Groups
  1. Biostatistics Service (8)
  2. Bone Marrow Transplant (8)
  3. CTCR Scholars (8)
  4. Center for Hematologic Malignancies (8)
  5. Department of Medicine (8)
  6. Epidemiology and Biostatistics (8)

More Groups

People
  1. Gunjan Shah (8)
  2. Jessica Flynn (8)
  3. Maria Palomba (8)
  4. Michael Scordo (8)
  5. Miguel-Angel Perales (8)
  6. Parastoo Dahi (8)

More People

Years
  1. 2024 (2)
  2. 2023 (3)
  3. 2022 (1)
  4. 2020 (2)
Publications
  1. Blood (2)
  2. International Journal of Radiation Oncology, Biology, Physics (2)
  3. Blood Advances (1)
  4. Clinical Cancer Research (1)
  5. Leukemia (1)
  6. Transplantation and Cellular Therapy (1)
Publishers
  1. American Society of Hematology (3)
  2. Elsevier Inc. (3)
  3. American Association for Cancer Research (1)
  4. Nature Publishing Group (1)

Results (8)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Improvement in radiomic features following bridging therapy is prognostic for CD19 chimeric antigen receptor (CAR) T-cell therapy outcome
    Meeting Abstract

    Hubbeling, H. G.; Leithner, D.; Silverman, E. A.; Flynn, J.; Devlin, S.; Shah, G. L.; Fregonese, B.; Bedmutha, A.; Boardman, A.; Dahi, P. B.; more...
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • Metabolic tumor volume response after bridging therapy determines chimeric antigen receptor T-cell outcomes in large B-cell lymphoma
    Journal Article

    Hubbeling, H.; Leithner, D.; Silverman, E. A.; Flynn, J.; Devlin, S.; Shah, G.; Fregonese, B.; Wills, B.; Bedmutha, A.; Alarcon Tomas, A.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Dynamics of radiomic features following bridging therapy determine CD19 chimeric antigen receptor (CAR) T-cell therapy outcome
    Meeting Abstract

    Hubbeling, H.; Leithner, D.; Silverman, E. A.; Flynn, J. R.; Devlin, S. M.; Shah, G. L.; Fregonese, B.; Bedmutha, A.; Wills, B.; Tomas, A. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Bridging radiation rapidly and effectively cytoreduces high-risk relapsed/refractory aggressive B cell lymphomas prior to chimeric antigen receptor T cell therapy
    Journal Article

    Hubbeling, H.; Silverman, E. A.; Michaud, L.; Tomas, A. A.; Shouval, R.; Flynn, J.; Devlin, S.; Wijetunga, N. A.; Tringale, K. R.; Batlevi, C.; more...
    Transplantation and Cellular Therapy (2023)

    Fulltext@MSK | Save
  • Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma
    Journal Article

    Alarcon Tomas, A.; Fein, J. A.; Fried, S.; Flynn, J. R.; Devlin, S. M.; Fingrut, W. B.; Anagnostou, T.; Alperovich, A.; Shah, N.; Fraint, E.; more...
    Leukemia (2023)

    Fulltext@MSK | Save
  • Patterns of relapse and risk reduction following tumor debulking by bridging radiotherapy prior to chimeric antigen receptor T cell therapy in non-Hodgkin lymphoma
    Meeting Abstract

    Hubbeling, H. G.; Silverman, E. A.; Michaud, L.; Flynn, J.; Devlin, S.; Wijetunga, N. A.; Alarcon Tomas, A.; Shouval, R.; Palomba, M. L.; Batlevi, C. L.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • Clinical impact of bridging therapy prior to commercial chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory lymphomas
    Meeting Abstract

    Imber, B. S.; Perales, M. A.; Flynn, J.; Ruiz, J. D.; Devlin, S.; Alarcon Tomas, A.; Hajj, C.; Batlevi, C. L.; Dahi, P. B.; Lin, R. J.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies
    Journal Article

    Sermer, D.; Batlevi, C.; Lia Palomba, M.; Shah, G.; Lin, R. J.; Perales, M. A.; Scordo, M.; Dahi, P.; Pennisi, M.; Afuye, A.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save